Phenotypes associated with this allele

• Allele Symbol: Rps6ka4^tm1Jsca
• Allele Name: targeted mutation 1, J Simon C Arthur
• Allele ID: MGI:3574670
• Summary: 3 genotypes

Jump to	Allelic Composition	Genetic Background	Genotype ID
cx1	Il10^tm1Cgn/Il10^tm1Cgn Rps6ka4^tm1Jsca/Rps6ka4^tm1Jsca Rps6ka5^tm1Jsca/Rps6ka5^tm1Jsca	B6.Cg-Il10^tm1Cgn Rps6ka5^tm1Jsca Rps6ka4^tm1Jsca	MGI:3809593
cx2	Rps6ka4^tm1Jsca/Rps6ka4^tm1Jsca Rps6ka5^tm1Jsca/Rps6ka5^tm1Jsca	B6.Cg-Rps6ka5^tm1Jsca Rps6ka4^tm1Jsca	MGI:3809592
cx3	Rps6ka4^tm1Jsca/Rps6ka4^tm1Jsca Rps6ka5^tm1Jsca/Rps6ka5^tm1Jsca	Not Specified	MGI:3716863

Genotype
MGI:3809593

cx1

• Allelic Composition: Il10^tm1Cgn/Il10^tm1Cgn; Rps6ka4^tm1Jsca/Rps6ka4^tm1Jsca; Rps6ka5^tm1Jsca/Rps6ka5^tm1Jsca
• Genetic Background: B6.Cg-Il10^tm1Cgn Rps6ka5^tm1Jsca Rps6ka4^tm1Jsca

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

immune system

decreased interleukin-10 secretion ( J:139576 )

• there is no IL-10 secretion from bone marrow derived macrophages after LPS stimulation

increased interleukin-12a secretion ( J:139576 )

• LPS stimulation of bone marrow derived macrophages leads to higher secretion of IL12a than in controls during an 8 hour time period

increased interleukin-12b secretion ( J:139576 )

• LPS stimulation of bone marrow derived macrophages leads to higher secretion of IL12b than in controls during an 8 hour time period

increased interleukin-6 secretion ( J:139576 )

• LPS stimulation of bone marrow derived macrophages leads to higher secretion of IL-6 than in controls during an 8 hour time period

increased tumor necrosis factor secretion ( J:139576 )

• LPS stimulation of bone marrow derived macrophages leads to higher secretion of TNF than in controls during an 8 hour time period

Genotype
MGI:3809592

cx2

• Allelic Composition: Rps6ka4^tm1Jsca/Rps6ka4^tm1Jsca; Rps6ka5^tm1Jsca/Rps6ka5^tm1Jsca
• Genetic Background: B6.Cg-Rps6ka5^tm1Jsca Rps6ka4^tm1Jsca

mortality/aging

increased susceptibility to induced morbidity/mortality ( J:139576 )

• less mice die 48 hours after sepsis induction by cecal ligation and puncture than in control

• 40% of mice die compared to 10% of wild-type mice subjected to the same sepsis model

immune system

abnormal cytokine level ( J:139576 )

decreased circulating interleukin-10 level ( J:139576 )

• LPS administration (1.8 mg/kg bodyweight) leads to significantly decreased levels of IL-10 four hours after administration compared to controls

• less IL-10 is also found in the plasma of mice undergoing sepsis from cecal ligation and puncture

increased circulating interleukin-12a level ( J:139576 )

• LPS administration (1.8 mg/kg bodyweight) leads to significantly increased levels of IL-12a four hours after administration compared to controls

increased circulating interleukin-12b level ( J:139576 )

• LPS stimulation of bone marrow derived macrophages leads to higher secretion of IL12b than in controls during an 8 hour time period

increased circulating interleukin-6 level ( J:139576 )

• LPS administration (1.8 mg/kg bodyweight) leads to significantly increased levels of IL-6 four hours after administration compared to controls

increased circulating tumor necrosis factor level ( J:139576 )

• LPS administration (1.8 mg/kg bodyweight) leads to significantly increased levels of TNF one hour after administration compared to controls

abnormal cytokine secretion ( J:139576 )

decreased interleukin-10 secretion ( J:139576 )

• LPS stimulation of bone marrow derived macrophages leads to decreased secretion of IL-10 than in controls during an 8 hour time period

• the discrepancy is greater during the early time points; 8 hours after stimulation secretion levels have reached 60% of wild-type

increased interleukin-12a secretion ( J:139576 )

• LPS stimulation of bone marrow derived macrophages leads to higher secretion of IL12a than in controls during an 8 hour time period

increased interleukin-12b secretion ( J:139576 )

• LPS stimulation of bone marrow derived macrophages leads to higher secretion of IL12b than in controls during an 8 hour time period

increased interleukin-6 secretion ( J:139576 )

• LPS stimulation of bone marrow derived macrophages leads to higher secretion of IL-6 than in controls during an 8 hour time period

increased tumor necrosis factor secretion ( J:139576 )

• stimulation of bone marrow derived macrophages leads to higher secretion of TNF than in controls during an 8 hour time period

increased susceptibility to endotoxin shock ( J:139576 )

• 2.5 mg/kg bodyweight causes LPS-induced toxicity in these mice while control mice are normal

• signs of toxicity include diarrhea, eye inflammation, piloerection, and a substantial drop in temperature within 4-8 hours of LPS injection

• mice were humanly sacrificed within 8 hours of LPS injection due to severity of symptoms

skin inflammation ( J:139576 )

• inflammation fails to resolve in phorbol 12-myristate 13-acetate (PMA) induced skin eczema of the ears

• ears of wild-type mice exposed to PMA swell from inflammatory infiltrate but resolve this swelling within 96 hours while mutant mice still have significant swelling 96 hours after PMA administration

• myeloperoxidase activity of ear extracts, a measure of polymorphonuclear cell recruitment, is significantly higher than controls both 72 and 96 hours after PMA administration

homeostasis/metabolism

abnormal cytokine level ( J:139576 )

decreased circulating interleukin-10 level ( J:139576 )

• LPS administration (1.8 mg/kg bodyweight) leads to significantly decreased levels of IL-10 four hours after administration compared to controls

• less IL-10 is also found in the plasma of mice undergoing sepsis from cecal ligation and puncture

increased circulating interleukin-12a level ( J:139576 )

• LPS administration (1.8 mg/kg bodyweight) leads to significantly increased levels of IL-12a four hours after administration compared to controls

increased circulating interleukin-12b level ( J:139576 )

• LPS stimulation of bone marrow derived macrophages leads to higher secretion of IL12b than in controls during an 8 hour time period

increased circulating interleukin-6 level ( J:139576 )

• LPS administration (1.8 mg/kg bodyweight) leads to significantly increased levels of IL-6 four hours after administration compared to controls

increased circulating tumor necrosis factor level ( J:139576 )

• LPS administration (1.8 mg/kg bodyweight) leads to significantly increased levels of TNF one hour after administration compared to controls

integument

skin inflammation ( J:139576 )

• inflammation fails to resolve in phorbol 12-myristate 13-acetate (PMA) induced skin eczema of the ears

• ears of wild-type mice exposed to PMA swell from inflammatory infiltrate but resolve this swelling within 96 hours while mutant mice still have significant swelling 96 hours after PMA administration

• myeloperoxidase activity of ear extracts, a measure of polymorphonuclear cell recruitment, is significantly higher than controls both 72 and 96 hours after PMA administration

Genotype
MGI:3716863

cx3

• Allelic Composition: Rps6ka4^tm1Jsca/Rps6ka4^tm1Jsca; Rps6ka5^tm1Jsca/Rps6ka5^tm1Jsca
• Genetic Background: Not Specified

immune system

decreased T cell proliferation ( J:124301 )

• T cells stimulated in vitro with anti-CD3 and anti-CD28 antibodies do not proliferate as well as wild-type cells

spleen hypoplasia ( J:124301 )

• at 6 weeks, mice have a reduction in the number of cells in the spleen

hematopoietic system

decreased T cell proliferation ( J:124301 )

• T cells stimulated in vitro with anti-CD3 and anti-CD28 antibodies do not proliferate as well as wild-type cells

spleen hypoplasia ( J:124301 )

• at 6 weeks, mice have a reduction in the number of cells in the spleen

cellular

decreased T cell proliferation ( J:124301 )

• T cells stimulated in vitro with anti-CD3 and anti-CD28 antibodies do not proliferate as well as wild-type cells